Compare
NeuroSense Therapeutics Ltd. vs Vaccinex, Inc. vs Polomar Health Services, Inc. vs Neonc Technologies Holdings, Inc.
| Latest fiscal year | NeuroSense Therapeutics Ltd. NRSN | Vaccinex, Inc. VCNXLast annual report: year ended 2024-12-31 | Polomar Health Services, Inc. PMHS | Neonc Technologies Holdings, Inc. NTHI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2024-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $601.0K | $648.2K | $40.0K |
| Revenue growth (YoY) | n/a | +5.4% | n/m | -51.8% |
| Gross margin | n/a | n/a | 71.0% | n/a |
| Operating margin | n/a | n/m | n/m | n/m |
| Net margin | n/a | n/m | n/m | n/m |
| Net income | -$11.12M | -$18.63M | -$10.70M | -$62.15M |
| EPS (Diluted) | -$0.44 | -$8.88 | -$0.39 | -$3.20 |
| Operating cash flow | -$7.67M | -$16.19M | -$396.0K | -$20.36M |
| Free cash flow | -$7.68M | -$16.21M | n/a | -$20.86M |
| Cash & equivalents | $166.0K | $1.11M | $132.2K | $58.7K |
| Total assets | $1.03M | $2.60M | $390.0K | $2.82M |
| Total liabilities | $2.59M | $5.08M | $1.61M | $20.33M |
| Shareholders' equity | -$1.56M | -$2.49M | -$1.22M | -$17.51M |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 32.56M | 2.68M | 28.02M | 21.99M |
Revenue, most recent five fiscal years
| Fiscal year | NeuroSense Therapeutics Ltd. | Vaccinex, Inc. | Polomar Health Services, Inc. | Neonc Technologies Holdings, Inc. |
|---|---|---|---|---|
| Latest | n/a | $601.0K Ended 2024-12-31 | $648.2K Ended 2025-12-31 | $40.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $570.0K Ended 2023-12-31 | $58.8K Ended 2024-12-31 | $83.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $275.0K Ended 2022-12-31 | $41.8K Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $900.0K Ended 2021-12-31 | $34.5K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $625.0K Ended 2020-12-31 | n/a | n/a |